ARTH - Arch Therapeutics, Inc.

Other OTC - Other OTC Delayed Price. Currency in USD

Arch Therapeutics, Inc.

235 Walnut Street
Suite 6
Framingham, MA 01702
United States
617-431-2313
http://www.archtherapeutics.com

SectorHealthcare
IndustryBiotechnology
Full Time Employees8

Key Executives

NameTitlePayExercisedYear Born
Dr. Terrence W. NorchiCo-Founder, Pres, CEO, Sec. & DirectorN/AN/A1965
Mr. Richard E. DavisChief Financial Officer and Treasurer331.25kN/A1958
Dr. Avtar S. DhillonBus. Advisor190kN/A1961
Mr. Rutledge Ellis-BehnkeCo-Founder & Scientific AdvisorN/AN/AN/A
Dr. Steven A. Kates Ph.D.VP of TechnologyN/AN/AN/A
Amounts are as of December 31, 2017 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Arch Therapeutics, Inc., operates as a biotechnology company in the United States. The company develops products based on its technology to stop bleeding and control leaking, as well as provides other advantages during surgery, trauma, and interventional care. Its primary product candidate is AC5 Devices, a synthetic biocompatible peptides that comprises naturally occurring amino acids to achieve hemostasis in minimally invasive and open surgical procedures. The company was founded in 2006 and is based in Framingham, Massachusetts.

Corporate Governance

Arch Therapeutics, Inc.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.